IGM Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 58.04 million compared to USD 44.16 million a year ago. Basic loss per share from continuing operations was USD 1.32 compared to USD 1.32 a year ago.
For the nine months, net loss was USD 168.53 million compared to USD 114.52 million a year ago. Basic loss per share from continuing operations was USD 4.15 compared to USD 3.43 a year ago.